- Home
- / Our solutions
Germany solutions
Our knowledge of the health care system is comprehensive and extensive – similar to our broad service portfolio.
More about Kintiga in Germany
We are partners of internationally operating pharma-, biotech and medtech companies, as well as of investors, whom we support as sparring partners, or whom we operationally guide through the entire market access process. As we enjoy facing strategic challenges, we particularly manage projects for orphan drug products, for ATMPs and for products which set new therapy standards.
Our expertise:
EU HTA
Our European team expertly navigates the complexities of EU HTA procedures, providing both strategic guidance & comprehensive end-to-end support for JSCs & JCAs at every stage of the process. We are committed to ensuring your products reach patients across Europe efficiently & effectively.
Digital Health Applications (DiGA) & Digital Pharma
For digital health applications, the path to reimbursement is the crucial hurdle of the market access process. Kintiga Germany provides comprehensive advice on how manufacturers can overcome the regulatory and market-specific hurdles.
Full Market Access
Full Market Access describes the entire process from the comprehensive, overarching and anticipating development of an overall cross-market strategy to its operational and proactive implementation in a complex and evolving environment with a simple-seeming goal: to help as many patients as possible at a fair price.
Strategic Due Diligence
Health care systems are complex and multi-layered constructs which must be penetrated in depth in order to place products successfully. Knowledge of history, trends and current developments in the industry environment helps innovators to integrate their products into existing systems. Based on this, decisive decisions on sustainability and marketability must be made in the innovation process.
Strategic Pricing
Pricing involves two key aspects: determining the launch price for a new product on the market and defining the reimbursement amount, i.e. the effective price that will be reimbursed by payers in the long term. The task of strategic pricing is therefore to develop the optimal strategy leading to the highest possible economic benefit and simultaneously enabling maximum market penetration.
Market Access Strategy
A market access strategy that has been precisely thought through and stringently implemented from the very beginning is the foundation for a fair reimbursement price for a pharmaceutical or medical technology product. This requires extensive knowledge of the market, the access process and possible hurdles.
Value Dossier
The value dossier represents more than a piece of paper. Because only when the evidence-based value arguments are combined with a convincing value story into one unit, new products and drugs can be marketed in a promising manner.
Benefit Assessment (AMNOG, Medical Devices)
New medication and new examination and treatment methods are subject to strict conditions. Manufacturers of medical technology and pharmaceuticals must consider this early for purposes of benefit assessment and must proceed strategically in order to position their products in the best possible manner.
Negotiation Support
Like in most European countries, the prices paid by the healthcare system for products and services in Germany are not administered but negotiated between the individual parties. Despite the highly regulated environment of the market access processes, there is considerable scope for shaping the contractual arrangements and agreeing the respective reimbursement amount.
Stakeholder Management
The success factors for a sustainable market access of innovative drugs and ATMPs are often based on the detailed work and the overall synchronization of all market access activities. The effective integration of relevant stakeholders and key opinion leaders can have a decisive impact on the success of the launch and must be an integral part of a winning market access strategy.
Contact us
Contact us to discover how we can support your journey towards patient access.
